|
Sign In to gain access to subscriptions and/or personal tools.
|
Synthetic Oligonucleotides: The Development of Antisense Therapeutics
David K. Monteith
Isis Pharmaceuticals, 2292 Faraday Avenue, Carlsbad, California 92008, dmonteith{at}isisph.com.
Arthur A. Levin
Isis Pharmaceuticals, Carlsbad, California 92008
Antisense therapeutics using synthetic oligodeoxynucleotides (ODNs) are currently being evaluated in clinical trials for cancer, inflammation, and viral diseases. These macromolecules afford a unique opportunity to treat disease at the molecular level. The specificity of these compounds is derived from the genetic code and Watson-Crick base pairing, utilizing an antisense paradigm for the inhibition of translation and the regulation of protein expression. Currently, most antisense ODNs in development contain a phosphorothioate (P=S) backbone. Additional modifications primarily involve the 2' position on the ribose or modification of the nucleotide linkages of the backbone. To date, no toxicities in animal models appear related to inhibition of the pharmacologic target, rather toxicities induced by P=S ODNs appear similar and are independent of pharmacologic target. In general, toxicities correlate well with pharmacokinetic or tissue distribution parameters. In primates, the primary acute effects are associated with complement activation and the systemic effects associated with accumulation of high concentrations of P=S ODNs in the kidneys. In rodents, the primary effect is an immune stimulation characterized by splenomegaly, lymphoid hyperplasia, and mononuclear cell infiltrates in multiple tissues. At extraordinarily high doses (15-50 times the targeted clinical doses), hepatocellular and renal tubular degeneration are evident in rodents. Second generation antisense compounds, new routes of administration, and new formulations appear to broaden and improve the application of antisense technology.
Key Words: Phosphorothioate oligonucleotides • antisense
References
- Agrawal S., Zhang X., Lu Z. Zhao H., Tamburin JM, Yan J., Cai H., Diasio RG, Habus I., Jlang Z., Iyer RP, Yu D., and Zhang R. (1995). Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration. Biochem. Pharmacol. 50: 571-576.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Altmann KH, Fabbro D., Dean NM, Geiger T., Monia BP, Muuler M., and Nicklin P. (1996). Second-generation antisense oligonucleotides: Structure-activity relationships and the design of improved signal transduction inhibitors. Biochem. Soc. Trans. 24: 630-637.[Web of Science][Medline]
[Order article via Infotrieve]
- Bennett CF (1998). Antisense oligonucleotides: Is the glass half full or half empty? Biochem. Pharmacol. 55: 9-19.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Bennett CF, Kornbrust D., Henry S., Stecker K., Howard R., Cooper S., Dutson S., Hall W., and Jacoby HI (1997). An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice. J. Pharmacol. Exp. Ther. 280: 988-1000.[Abstract/Free Full Text]
- Bennett CF, Zuckerman JE, Kornbrust D., Sasmor H., Leeds JM, and Crooke ST (1996). Pharmacokinetics in mice of a [3H]-labeled phosphorothioate oligonucleotide formulated in the presence and absence of a cationic lipid. J. Controlled Release 41: 121-130.[CrossRef][Web of Science]
- Crooke ST (1993). Progress toward oligonucleotide therapeutics: Pharmacodynamic properties. FASEB 7: 533-539.[Abstract]
- Crooke ST (1995). Oligonucleotide therapeutics. In: Burger's Medicinal Chemistry and Drug Discovery, Vol. 1, 5th ed., ME Wolff (ed). Wiley and Sons, New York, pp. 863-900.
- Crooke ST, Graham MJ, Zuckerman JE, Brooks D., Conklin BS, Cummins LL, Greig MJ, Guinosso CJ, Kornbrust D., Manoharan M., Sasmor HM, Schleich T., Tivel KL, and Griffey RH (1996). Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J. Pharmacol. Exp. Ther. 277: 923-937.[Abstract/Free Full Text]
- Dean NM and Griffey RH (1997). Identification and characterization of second-generation antisense oligonucleotides. Antisense Nucleic Acid Drug Dev. 7: 229-233.[Web of Science][Medline]
[Order article via Infotrieve]
- Dean NM and McKay R. ( 1994). Inhibition of protein kinase C-
 expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA 91: 11762-11766.[Abstract/Free Full Text] - Diamantstein T., Wagner B., Beyse I., Odenwald MV, and Schultz G. (1971). Stimulation of humoral antibody formation by polyanions. II. The influence of sulfate esters of polymers on the immune response in mice. Eur. J. Immunol. 1: 340-343.[Medline]
[Order article via Infotrieve]
- Galbraith WM, Hobson WC, Giclas PC, Schechter PJ, and Agrawal S. (1994). Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res. Dev. 4: 201-206.[Web of Science][Medline]
[Order article via Infotrieve]
- Geary RS, Leeds JM, Fitchett J., Burckin T., Troung L., Spainhour C., Creek M., and Levin AA (1997). Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression. Drug Metab. Dispos. 25: 1272-1281.[Abstract/Free Full Text]
- Geary RS, Leeds JM, Henry SP, Monteith DM, and Levin AA (1997). Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. Anti-Cancer Drug Des. 12: 383-394.[Medline]
[Order article via Infotrieve]
- Griffey RH, Lesnik E., Frier S., Sanghvi YS, Teng K., Kawasaki A., Guinoso C., Wheeler P., Mohan V., and Cook PD (1994). New twists on nucleic acids: Structural properties of modified nucleosides incorporated into oligonucleotides. In Carbohydrate Modifications in Antisense Research, Vol. 580, YS Sanghvi and PD Cook (eds). American Chemical Society, Washington, D.C., pp. 212-224.
- Henry SP, Bolte H., Auletta C., and Kornbrust DJ (1997). Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in cynomolgus monkeys. Toxicology 120: 145-155.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Henry SP, Giclas PC, Leeds J., Pangburn M., Auletta C., Levin AA, and Kornbrust DJ (1997). Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: Potential mechanism of action. J. Pharmacol. Exp. Ther. 281: 810-816.[Abstract/Free Full Text]
- Henry SP, Grillone LR, Orr JL, Brunner RH, and Kornbrust DJ (1997). Comparison of the toxicity profiles of ISIS 1082 and ISIS 2105, phosphorothioate oligonucleotides, following subacute intradermal administration in Sprague-Dawley rats. Toxicology 116: 77—88.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Henry SP, Monteith D., and Levin AA (1997). Antisense oligonucleotide inhibitors for the treatment of cancer: 2. Toxicologic properties of phosphorothioate oligodeoxynucleotides. Anti-Cancer Drug Des. 12: 395-408.[Medline]
[Order article via Infotrieve]
- Henry SP, Novotny W., Leeds J., Auletta C., and Kornbrust DJ (1997). Inhibition of coagulation by a phosphorothioate oligonucleotide. Antisense Nucleic Acid Drug Dev. 7: 503—510.[Web of Science][Medline]
[Order article via Infotrieve]
- Henry SP, Taylor J., Midgley L., Levin AA, and Kornbrust DJ (1997). Evaluation of the toxicity profile of ISIS 2302, a phosphorothioate oligonucleotide in a 4-week study in CD-1 mice. Antisense Nucleic Acid Drug Dev. 7: 473-481.[Web of Science][Medline]
[Order article via Infotrieve]
- Homan ER, Zendzian RP, Schott LD, Levy HB, and Adamson RH (1972). Studies on poly I: C toxicity in experimental animals. Toxicol. Appl. Pharmacol. 23: 579-588.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Horner MJ, Monteith DK, Gillett NA, Butler M., Henry SP, Bennett CF, and Levin AA (1997). Evaluation of the renal effects of phosphorothioate oligonucleotides in monkeys. Fundam. Appl. Toxicol. 36(suppl.): 147 (abstract).
- Kuramoto E., Yano O., Kimura Y., Baba M., Makino T., Yamamoto S., Yamamoto T., Kataoka T., and Tokonaga T. (1992). Oligonucleotide sequences required for natural killer cell activation. Jpn. J. Cancer Res. 83: 1128-1131.[CrossRef][Web of Science]
- Leonetti C., Dagnano I., Lozupone F., Valentini A., Geiser T., Zon G., Calabretta B., Citro G., and Zupi G. (1996). Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and in mice. J. Natl. Cancer Inst. 88: 419-429.[Abstract/Free Full Text]
- Ma L. and Calvo F. (1996). Recent status of the antisense oligonucleotide approaches in oncology. Fundam. Clin. Pharmacol. 10: 97-115.[Web of Science][Medline]
[Order article via Infotrieve]
- Mandiyan S., Schumacher C., Cioffi C., Sharif H., Yuryev A., Lappe R., Monia B., Hanson S., Goff S., and Wennogle L. ( 1997). Molecular and cellular characterization of baboon C-Raf as a target for antiproliferative effects of antisense oligonucleotides. Antisense Nucleic Acid Drug Dev. 7: 539-548.[Web of Science][Medline]
[Order article via Infotrieve]
- Manoharan M., Tivel KL, Condon TP, Andrade LK, Barber-Peoch I., Inanmati G., Shah S., Mohan V., Graham MJ, Bennett CF, Crooke ST, and Cook PD (1997). Conjugated antisense oligonucleotides. Nucleosides Nucleotides 16: 1129-1138.[CrossRef][Web of Science]
- Manza LL, Butler MM, Bennett CF, Levin AA, de Peyster AA, and Monteith DK (1997). Renal toxicity of phosphorothioate oligonucleotides in rats. Fundam. Appl. Toxicol. 36(suppl.): 147 (abstract).
- Monia BP, Sasmor H., Johnston JF, Freier SM, Lesnik EA, Muller M., Geiger T., Altmann KH, Moser H., and Fabbro D. (1996). Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human c-raf kinase supports an antisense mechanism of action in vivo. Proc. Natl. Acad. Sci. USA 93: 15481-15484.[Abstract/Free Full Text]
- Monteith DK Geary RS Leeds JM, Johnston J. Monia BP, and Levin AA (1998). Preclinical evaluation of the effects of a novel antisense compound targeting C-raf kinase in mice and monkeys. Toxicol. Sci. 46: (in press).
- Monteith DK, Henry SP Howard RB, Flournoy S., Levin AA, Bennett CF, and Crooke ST (1997). Immune stimulation—A class effect of phosphorothioate oligodeoxynucleotides in rodents. AntiCancer Drug Des. 12: 421-432.[Medline]
[Order article via Infotrieve]
- Phillips JA, Craig SJ, Bayley D., Christian RA, Geary R., and Nicklin PL (1997). Pharmacokinetics, metabolism and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration. Biochem. Pharmacol. 54: 657-668.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Pisetsky DS and Reich CF (1994). Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus. Life Sci. 54: 101-107.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Sarmiento UM, Perez JR, Becker JM, and Ramaswamy N. (1994). In vivo toxicological effects of rel A antisense phosphorothioates in CD-1 mice. Antisense Res. Dev. 4: 99-107.[Web of Science][Medline]
[Order article via Infotrieve]
- Shimada S., Yano O., and Tokunaga T. (1986). In vivo augmentation of natural killer cell activity with a deoxyribonucleic acid fraction of BCG. Jpn. J. Cancer Res. 77: 808-816.[Web of Science]
- Stepkowski SM, Tu Y., Condon TP, and Bennett CF (1994). Blocking of heart allograft rejection by intercellular adhesion molecule-1 antisense oligonucleotides alone or in combination with other immunosuppressive modalities. J. Immunol. 153: 5336-5346.[Abstract]
- Tokunaga T., Yamamato S., and Namba K. (1988). A synthetic single-stranded DNA, poly (dG, dC), induces interferon-/β and -
 augments natural killer activity, and suppresses tumor growth. Jpn. J. Cancer Res. 79: 682-686.[CrossRef][Web of Science] - Yamamoto T., Yamamoto S., Kataoka T., and Tokunaga T. (1994). Ability of oligonucleotides with certain palindromes to induce interferon production and augment natural killer cell activity is associated with their base length. Antisense Res. Dev. 4: 119-122.[Web of Science][Medline]
[Order article via Infotrieve]
- Yazaki T., Ahmad S., Chahlavi A., Zylber-Katz E., Dean NM, Rabkin SD, Martuza RL and Glazer RI (1996). Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide. Mol. Pharmacol. 50: 236-242.[Abstract]
Toxicologic Pathology, Vol. 27, No. 1,
8-13 (1999)
DOI: 10.1177/019262339902700103
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
A. M. Krieg
Antiinfective Applications of Toll-like Receptor 9 Agonists
Proceedings of the ATS,
July 1, 2007;
4(3):
289 - 294.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Hayashi, H. Banno, K. Kadomatsu, Y. Takei, K. Komori, and T. Muramatsu
Antisense oligodeoxyribonucleotide as to the growth factor midkine suppresses neointima formation induced by balloon injury
Am J Physiol Heart Circ Physiol,
May 1, 2005;
288(5):
H2203 - H2209.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Wasmuth, D. Bauer, Y. Yang, K.-P. Steuhl, and A. Heiligenhaus
Topical Treatment with Antisense Oligonucleotides Targeting Tumor Necrosis Factor-{alpha} in Herpetic Stromal Keratitis
Invest. Ophthalmol. Vis. Sci.,
December 1, 2003;
44(12):
5228 - 5234.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Stewart, R. C. Donehower, E. A. Eisenhauer, N. Wainman, A. K. Shah, C. Bonfils, A. R. MacLeod, J. M. Besterman, and G. K. Reid
A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly
Ann. Onc.,
May 1, 2003;
14(5):
766 - 774.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Farman and D. J. Kornbrust
Oligodeoxynucleotide Studies in Primates: Antisense and Immune Stimulatory Indications
Toxicol Pathol,
January 1, 2003;
31(1_suppl):
119 - 122.
[Abstract]
[PDF]
|
|
|
|
|
|
|
Y. Takei, K. Kadomatsu, H. Itoh, W. Sato, K. Nakazawa, S. Kubota, and T. Muramatsu
5'-,3'-Inverted Thymidine-modified Antisense Oligodeoxynucleotide Targeting Midkine. ITS DESIGN AND APPLICATION FOR CANCER THERAPY
J. Biol. Chem.,
June 21, 2002;
277(26):
23800 - 23806.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Q. Sun, M. J. Cairns, E. G. Saravolac, A. Baker, and W. L. Gerlach
Catalytic Nucleic Acids: From Lab to Applications
Pharmacol. Rev.,
September 1, 2000;
52(3):
325 - 348.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. M. McGuffie, D. Pacheco, G. M. R. Carbone, and C. V. Catapano
Antigene and Antiproliferative Effects of a c-myc-targeting Phosphorothioate Triple Helix-forming Oligonucleotide in Human Leukemia Cells
Cancer Res.,
July 1, 2000;
60(14):
3790 - 3799.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
R Haworth and A M Pilling
The PCR assay in the preclinical safety evaluation of nucleic acid medicines
Human and Experimental Toxicology,
May 1, 2000;
19(5):
267 - 276.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. M. Pilling
The Role of the Toxicologic Pathologist in the Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals
Toxicol Pathol,
November 1, 1999;
27(6):
678 - 688.
[Abstract]
[PDF]
|
|
|
|
|
